Overview of Dr. Sawas
Dr. Ahmed Sawas is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 11 years. He is one of 368 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 30 publications and over 500 citings.
Office
161 Fort Washington Avenue
0
New York, NY 10032- Is this information wrong?
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012- Westchester Medical CenterResidency, Internal Medicine, 2006 - 2009
State University of New York Downstate Medical Center College of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2009 - 2025
Clinical Trials
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Start of enrollment: 2013 Mar 01
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
- Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
- Join now to see all
Publications & Presentations
PubMed
- Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-...Brian Estrella, Mark M Francescone, Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Ahmed Sawas, Jennifer K Lue, Barbara Pro, Jennifer E Amengual> ;Leukemia & Lymphoma. 2024 Mar 22
- Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.Polito, L., Liang, Q., Pal, N., Mpofu, P., Humblet, O., Rufibach, K., Heinzmann, D., Sawas, A.> ;Frontiers in Pharmacology. 2024 Jan 1
- RWD-derived response in multiple myeloma.Tao Xu, James Roose, Mellissa Williamson, Ahmed Sawas, Wan-Jen Hong, Huan Jin, Kathleen Maignan, Alberto Rocci, Kasra Yousefi, Shaji Kumar, Stefka Tyanova> ;Plos One. 2023 Jan 1
- Join now to see all
Journal Articles
- Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin LymphomaChangchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology
Press Mentions
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-Positive LymphomaDecember 7th, 2020
Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
Affimed Reports Financial Results for Third Quarter 2018 and Operational ProgressNovember 7th, 2018
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
